Recombinant Human IL5RA protein, Fc-tagged
Cat.No. : | IL5RA-327H |
Product Overview : | Recombinant Human IL5RA protein (Asp21-Trp342), fused to human IgG1 Fc tag at C-terminus, was expressed in human 293 cells (HEK293). |
- Specification
- Gene Information
- Related Products
Description : | Interleukin-5 receptor subunit alpha (IL5RA) is also known as IL-5 receptor subunit alpha, IL-5R subunit alpha and CD125, which is a single-pass type I membrane protein that belongs to the type I cytokine receptor family and type 5 subfamily.IL5R, a heterodimer of an alpha and a beta subunit, is expressed on eosinophils and basophils. IL5RA/CD125 is the receptor for interleukin-5 (IL5) and the alpha chain can bind to IL5. The WSXWS motif of IL5RA appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.The beta subunit of IL5R is common to the IL3, IL5 and GM-CSF receptors. |
Source : | HEK293 |
Species : | Human |
Tag : | human IgG1 Fc |
Form : | Lyophilized from 0.22 um filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose. |
Molecular Mass : | The protein has a calculated MW of 63.2 kDa. The protein migrates as 70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | 322 |
Endotoxin : | Less than 1.0 EU per ug by the LAL method. |
Purity : | >90% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 centigrade to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | IL5RA |
Official Symbol : | IL5RA |
Synonyms : | IL5R; CD125; CDw125; HSIL5R3 |
Gene ID : | 3568 |
mRNA Refseq : | NM_000564.4 |
Protein Refseq : | NP_000555.2 |
MIM : | 147851 |
UniProt ID : | Q01344 |
Products Types
◆ Recombinant Protein | ||
IL5RA-334H | Recombinant Human IL5RA Protein, His-tagged | +Inquiry |
IL5RA-241I | Active Recombinant Human IL5RA Protein | +Inquiry |
IL5RA-069H | Recombinant Human IL5RA Protein, C-His-tagged | +Inquiry |
IL5RA-5176H | Recombinant Human IL5RA Protein | +Inquiry |
Il5ra-77M | Recombinant Mouse Il5ra Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
IL5RA-001MCL | Recombinant Mouse IL5RA cell lysate | +Inquiry |
IL5RA-2060HCL | Recombinant Human IL5RA cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionRecombinant IL5RA can be used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. It can reduce the frequency and severity of asthma attacks by blocking the signaling of interleukin 5.
Currently, recombinant IL5RA is mainly used to treat IL5-related diseases, such as severe asthma and eosinophilic diseases. For other diseases, the suitability of IL5RA is subject to further research and clinical trials.
During the use of IL5RA, the doctor may ask to check the patient's blood routine regularly to monitor changes in blood counts and related indicators. This helps to evaluate the efficacy of the treatment and the safety of the patient.
There is no clear evidence that long-term use of recombinant IL5RA causes dependence. For patients using IL5RA, it is best to treat and discontinue the drug according to the advice and guidance of their doctor.
IL5RA is generally administered by subcutaneous injection. The specific use method and dosage should be determined according to the doctor's recommendation and the specific situation of the patient.
Common side effects of recombinant IL5RA include pain at the injection site, redness and swelling at the injection site, cough, and sore throat. A small number of patients may experience allergic reactions or serious adverse reactions, so close monitoring of the patient's condition and signs is required when using.
Customer Reviews (3)
Write a reviewGood stability under different temperature and humidity conditions.
In the process of purification, the removal of impurities is good.
Chemical modifications, such as PEGylation or glycosylation, have little effect.
Ask a Question for All IL5RA Products
Required fields are marked with *
My Review for All IL5RA Products
Required fields are marked with *
Inquiry Basket